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Poster Session I S221cells/kg/Dose). Tumor responses, EBV DNA levels and quantita-
tions of tetramer+, IFNg+ EBV-specific T-cells and EBV CTLp
by limiting dilution analysis (LDA) were monitored. Infusions
were well tolerated; no pt developed GVHD.
Of the 22 pts, 3 died too early to be evaluated (\10 days). Of 6
pts primarily treated with EBV-CTL, 5 (83%) achieved CR, ver-
sus 7/13 (53%) who failed Rituxan. The CR rate was similar in pts
on no immunosuppressives or on Sirolimus or Calcineurin inhib-
itors alone (75% with; 67% without), but was lower for pts on ste-
roids for GVHD or cerebral edema (33%) than for pts off steroids
(69%). Pts with single sites of disease fared better than pts with
multiple sites (75% vs. 42% CR). However, all sites of disease, in-
cluding CNS, were comparably responsive to therapy. CTLp fre-
quencies rose 10-200 fold by 2-3 weeks post infusion in pts
achieving CR and were temporally associated with disease regres-
sion and clearance of EBV DNA. Such increases were not seen in
any pt with PD. EBV CTLs inducing CRs in 8 pts studied lysed
both B95.8 EBVBLCL and spontaneous EBV+ BLCL transform-
ants (S-EBV BLCL) isolated from the pt’s blood or involved tis-
sues; EBV CTL given to 3 non-responders on no
immunosuppression lysed B95.8+ BLCL, but not S-EBVBLCL
of donor origin isolated from the pt.
While EBVCTL can induce durable remissions of EBV lym-
phoma post HSCT, efficacy may be compromised in Rituxan refrac-
tory disease, by ongoing steroid treatment or by failure of the
EBVCTL to recognize the endogenous EBV the pt’s lymphoma.171
IMPROVED T CELL RECOVERY AFTER TRANSPLANTATION OF CD3/CD19
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Profound depletion of T and B cells is a fundamental prerequisite
for haploidentical transplantation and allows tominimizeGvHDde-
spite HLA incompatibility. However, posttransplant recovery of do-
nor derived T cells is delayed after various graft manipulation
procedures and may result in severe infections. Methods to improve
this recovery are of importance. Here we present immune reconsti-
tution data in patients who received CD3/CD19 depleted stem cells
in combination with melphalan based or standard conditioning reg-
imens. 32 patients with ALL(n5 14), AML/MDS n5 17),
CML(n5 1) were included. T- and B-cells were directly depleted
using antiCD3/antiCD19 coatedmagneticmicrobeads and the Clin-
iMACS device. The patients received either TBI or Bu i.v. and
OKT3(n5 9) or a reduced intensity conditioning (‘‘RIC’’: Mel
140 mg/m2, Flud 160 mg/m2, TT 10 mg/kg, OKT3, n5 23).
Absolute numbers of lymphocyte subsets per microliter on day 90
were compared within these both groups and with a historical con-
trol group (patients with leukemias who received CD34 selected
grafts and TBI or Bu based standard conditioning regimen in com-
bination with ATG, n5 28).
CD3 + 4+, CD3 + 8+ and total numbers of CD3+ of patients after
CD3/CD19 depletion were significantly higher in the RIC-group
than in the TBI/Bu-group (mean: 85.83 vs. 38.84; 133.46 vs.
19.69; 270.27 vs. 63.99; p\0.05, t-test).
Comparisonwith thewholeCD34historical group showed a faster
recovery of CD3 + 4+ in patients with CD3/19 depletion and RIC
(104.26 vs. 54.22; p5 0,034) but no significant difference in
CD3 + 8+ and CD3+. Furthermore, subgroups of the CD34 histor-
ical population were compared: patients with CD3/19 depletion
and RIC had a significantly faster recovery of CD3 + 4+, CD3 + 8+
and CD3+ than CD34 patients with TBI (104.26vs. 25.48;
133.46vs. 43.17; 270.27 vs. 65.86; p\0.05) but had no advantage
over CD34 patients with non-TBI conditioning.
Conclusions: the type of graft manipulation appeared to have an
influence on the speed of CD4+ recovery (CD3/19 deple-
tion.CD34 selection). Moreover, the use of TBI had a negative
impact on all T cell subsets: patients with TBI had a slower recov-
ery than patients with non-TBI conditioning, independent from
graft manipulation procedures and probably due to thymic dam-
age. Thus, the use of RIC-protocols in combination with CD3/CD19 depletion may help to speed up the immune recovery after
haploidentical transplantation. Further studies are warranted to
evaluate the risk of relapse.172
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Graft versus Host Disease (GVHD) and infectious complications
are the main cause of morbidity and mortality after allogeneic blood
or marrow transplantation (allo-BMT). Currently, there is no objec-
tive laboratory assay to assess the level of immunereactivity to poten-
tially predict the risk of complications in allo-BMT patients. The
Cylex ImmuKnow assay is approved by theUSFood andDrug Ad-
ministration for detection of cell mediated immunity in immunosup-
pressed individuals. This assay measures immune response to
stimulation by detecting ATP synthesis in CD4 T cells following
phytohemagglutinin (PHA) stimulation. We prospectively studied
PHA-induced ATP release in 20 allo-BMT patients weekly from
day +15 until day +100 post-transplantation. We tested 224 blood
samples with an average of 11.2 per patient (SD 1.8). Patients re-
ceived grafts from matched unrelated (MUD, n5 11 [55%]),
matched related (MRD, n5 8 [40]) and syngeneic donors (n5 1).
Myeloablative and nonmyeloablative conditioning regimens were
used in 13 (65%) and 7 (35%) patients, respectively. 12 patients
(60%) developed GVHD requiring treatment, 2 (10%) developed
GVHD which did not require treatment, and 6 (30%) did not de-
velop any GVHD. Cyclosporine levels (n5 19) did not correlate
with ATP response, nor did the graft composition (CD34+ cells/
kg or the CD3+ cells/kg). Further, we determined that the maximum
ATP level was not a significant predictor of GVHD incidence, nor
was the maximum fold increase over baseline. However, we observed
worse outcomes in patients who had sustained low ATP levels as de-
fined by 3 consecutive measurements of ATP\75 ng/mL.We found
a significant correlation between persistently suppressed ATP levels
and death (p5 0.013). In all patients who died (n5 7), ATP levels
were persistently low and did not recover. In contrast, all 9 patients
who exhibited ATP levels .75ng/ml are alive. Patients who main-
tained an average of .100 ng/ml ATP (mean 235 ng/ML, range
114-402 ng/mL) at monthly intervals did not have GVHD (n5 6)
or require therapy for GVHD (n5 2). Conversely, patients with
ATP levels \100 ng/mL at monthly intervals were treated for
GVHD (mean 84.4 ng/mL, range 24-318ng/mL). Our data suggest
that a persistent immunocompromised state in BMT recipients is as-
sociated with poor outcome. A larger study is warranted to analyze
the utility of the Cylex ImmuKnow assay in BMT patients, which
may enable us to predict outcomes and tailor immunosuppressive
therapy.173
TEMPORARY LICENSING OF HYPORESPONSIVE NK CELLS FOLLOWING
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InHLA-matchedT-cell depleted (TCD)HCT, recipients lacking
class I ligands for donor inhibitory KIR have lower relapse and
higher survival. The ‘‘missing ligand’’ effect on clinical outcome is
likely due to temporary licensing post-transplant of the normally hy-
poresponsiveNK cells expressingKIR for non-selfHLA ligands. Be-
cause the KIR-expressing NK repertoire following HCT can be
affected by T-cells in the allograft, we examined NK functional re-
constitution in recipients of unmodified HCT. We assessed NK
function in 10 patients following unmodified stem cell
